SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
SciSparc (Nasdaq: SPRC) has announced a significant development in its collaboration with Clearmind Medicine Inc. Clearmind has published a patent application for innovative combinations of ketamine and N-acylethanolamines. This collaboration focuses on researching combination treatments using SciSparc's Palmitoylethanolamide (PEA) and Clearmind's psychedelic molecule, MEAI, for treating addictions, weight loss, and mental health disorders.
The partnership has already resulted in thirteen patent applications filed with the U.S. Patent and Trademark Office and other global patent offices. SciSparc's approach aims to reduce the number of doses of active ingredients while maintaining effectiveness and minimizing side effects, potentially improving treatment outcomes for various medical conditions.
SciSparc (Nasdaq: SPRC) ha annunciato un importante sviluppo nella sua collaborazione con Clearmind Medicine Inc. Clearmind ha pubblicato una domanda di brevetto per combinazioni innovative di ketamina e N-acilethanolammine. Questa collaborazione si concentra sulla ricerca di trattamenti combinati utilizzando il Palmitoiletanolamide (PEA) di SciSparc e la molecola psichedelica di Clearmind, MEAI, per il trattamento di dipendenze, perdita di peso e disturbi mentali.
La partnership ha già prodotto tredici domande di brevetto depositate presso l'Ufficio Brevetti e Marchi degli Stati Uniti e altri uffici brevi globali. L'approccio di SciSparc mira a ridurre il numero di dosi di principi attivi mantenendo l'efficacia e minimizzando gli effetti collaterali, potenzialmente migliorando i risultati terapeutici per diverse condizioni mediche.
SciSparc (Nasdaq: SPRC) ha anunciado un desarrollo significativo en su colaboración con Clearmind Medicine Inc. Clearmind ha publicado una solicitud de patente para combinaciones innovadoras de ketamina y N-acilethanolaminas. Esta colaboración se centra en investigar tratamientos combinados utilizando el Palmitoiletanolamida (PEA) de SciSparc y la molécula psicodélica de Clearmind, MEAI, para tratar adicciones, pérdida de peso y trastornos de salud mental.
La asociación ya ha dado lugar a trece solicitudes de patente presentadas ante la Oficina de Patentes y Marcas de Estados Unidos y otras oficinas de patentes a nivel global. El enfoque de SciSparc busca reducir el número de dosis de ingredientes activos mientras mantiene la efectividad y minimiza los efectos secundarios, mejorando potencialmente los resultados del tratamiento para diversas condiciones médicas.
SciSparc (Nasdaq: SPRC)는 Clearmind Medicine Inc.와의 협력에서 중요한 개발을 발표했습니다. Clearmind는 케타민과 N-아실에탄올아민의 혁신적인 조합에 대한 특허 출원을 발표했습니다. 이 협력은 SciSparc의 팔미토일에탄올아미드(PEA)와 Clearmind의 정신활성 물질 MEAI를 사용한 조합 치료 연구에 중점을 두고 있으며, 중독, 체중 감소 및 정신 건강 장애 치료를 목표로 하고 있습니다.
이 파트너십은 이미 미국 특허청과 다른 글로벌 특허청에 열세 개의 특허 출원을 제출하는 결과를 가져왔습니다. SciSparc의 접근 방식은 활성 성분의 복용량을 줄이면서 효과를 유지하고 부작용을 최소화하여 다양한 의학적 상태의 치료 결과를 개선할 가능성이 있습니다.
SciSparc (Nasdaq: SPRC) a annoncé un développement significatif dans sa collaboration avec Clearmind Medicine Inc. Clearmind a publié une demande de brevet pour des combinaisons innovantes de kétamine et N-acyléthanolamines. Cette collaboration se concentre sur la recherche de traitements combinés utilisant le Palmitoyléthanolamide (PEA) de SciSparc et la molécule psychédélique de Clearmind, MEAI, pour traiter les dépendances, la perte de poids et les troubles de la santé mentale.
Le partenariat a déjà conduit à treize demandes de brevet déposées auprès de l'Office des brevets et des marques des États-Unis, ainsi que d'autres bureaux de brevets à l'échelle mondiale. L'approche de SciSparc vise à réduire le nombre de doses des principes actifs tout en maintenant l'efficacité et en minimisant les effets secondaires, améliorant ainsi potentiellement les résultats des traitements pour diverses conditions médicales.
SciSparc (Nasdaq: SPRC) hat eine bedeutende Entwicklung in seiner Zusammenarbeit mit Clearmind Medicine Inc. bekannt gegeben. Clearmind hat einen Patentantrag für innovative Kombinationen von Ketamin und N-Acylethanolaminen veröffentlicht. Diese Zusammenarbeit konzentriert sich auf die Erforschung von Kombinationstherapien unter Verwendung von SciSparc's Palmitoylethanolamid (PEA) und der psychedelischen Moleküle von Clearmind, MEAI, zur Behandlung von Abhängigkeiten, Gewichtsverlust und psychischen Erkrankungen.
Die Partnerschaft hat bereits zu dreizehn Patentanträgen beim US-Patent- und Markenamt sowie anderen globalen Patentämtern geführt. Der Ansatz von SciSparc zielt darauf ab, die Anzahl der Dosen aktiver Inhaltsstoffe zu reduzieren, während die Wirksamkeit beibehalten und Nebenwirkungen minimiert werden, was potenziell die Behandlungsergebnisse für verschiedene medizinische Bedingungen verbessern könnte.
- Publication of patent application for innovative ketamine-based combinations
- Thirteen patents filed related to the collaboration
- Potential to reduce doses while maintaining effectiveness and minimizing side effects
- Expanding research into treatments for addictions, weight loss, and mental health disorders
- None.
The collaboration between SciSparc and Clearmind Medicine on ketamine-based combinations represents a significant development in the field of psychedelic-derived therapeutics. The publication of their patent application underscores the potential for innovative treatments targeting mental health disorders, addictions and weight loss.
The focus on combining ketamine with N-acylethanolamines, particularly SciSparc's PEA, could potentially address the limitations of current ketamine treatments. By potentially reducing the required dosage and minimizing side effects, this approach may expand the applicability of ketamine-based therapies beyond the current FDA-approved uses for treatment-resistant depression.
With 13 patents filed related to this collaboration, the companies are building a robust intellectual property portfolio. This strategic move could position them favorably in the rapidly evolving psychedelic medicine market, potentially leading to lucrative licensing opportunities or partnerships with larger pharmaceutical companies.
The collaboration between SciSparc and Clearmind Medicine presents an intriguing approach to addressing the limitations of current ketamine treatments. By combining ketamine with N-acylethanolamines, particularly PEA, the researchers aim to maintain efficacy while reducing dosage and side effects. This could potentially expand the therapeutic applications of ketamine beyond its current FDA-approved uses.
The focus on treating addictions, weight loss and mental health disorders with this combination therapy aligns with growing clinical interest in psychedelic-assisted treatments. If successful, this approach could offer new options for patients who have not responded to traditional therapies.
However, it's important to note that extensive clinical trials will be necessary to demonstrate the safety and efficacy of these novel combinations. The strict usage guidelines for current ketamine treatments highlight the need for careful evaluation of any new formulations.
TEL AVIV, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has announced the publication of its patent application under the international Patent Cooperation Treaty, for innovative combinations of ketamine and N-acylethanolamines.
SciSparc and Clearmind, as part of their collaboration, research combination treatment comprised of SciSparc’s Palmitoylethanolamide (“PEA”) and Clearmind’s innovative psychedelic molecule, MEAI, for treating addictions, weight loss and mental health disorders. Furthermore, SciSparc and Clearmind are jointly exploring new treatments based on psychedelic molecules and PEA. To date, thirteen patents related to this collaboration have been filed with the U.S. Patent and Trademark Office and several other global patent offices.
The U.S. Food & Drug Administration (the “FDA”) gave its approval in 2019 for a ketamine derivative as a nasal spray medication, intended for two specific uses in adult patients: treating depression that has not responded to other treatments and alleviating depressive symptoms in those with major depressive disorder who are having suicidal thoughts or exhibiting suicidal behavior.
The approved treatment comes with strict usage guidelines. It must be administered only at certified medical facilities and used alongside an antidepressant medication. After receiving a dose, patients are required to remain at the facility for a two-hour observation period. This allows healthcare providers to monitor for any potentially serious side effects that may occur.
“SciSparc has always been focused on the development of unique and proprietary combinations with PEA, which our research shows can dramatically reduce the number of doses of various active ingredients while maintaining effectiveness and minimizing adverse effects. Ketamine was approved by the FDA for use under close supervision due to its accompanying side effects. Our innovative approach aims to deliver therapeutic benefits to a diverse group of patients with various conditions, while minimizing unwanted adverse effects. We believe this approach could improve treatment outcomes across a broad spectrum of medical needs,” said Oz Adler, Chief Executive Officer of SciSparc.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward looking statements when discussing ongoing collaborative research, the prospective outcomes and effects of SciSparc’s collaborative research with Clearmind, and the belief that SciSparc’s approach to its research may improve treatment outcomes. Since such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the SEC on April 1, 2024, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
FAQ
What is the focus of SciSparc's collaboration with Clearmind Medicine?
How many patents has the SciSparc-Clearmind collaboration filed so far?
What is the potential benefit of SciSparc's approach to drug combinations?
What is the stock symbol for SciSparc ?
